Robert P Giugliano MD, SM, FACC, FAHAAssociate Professor of Medicine, Harvard Medical School; Associate Physician, Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
Dr. Giugliano is currently an Associate Physician in the Cardiovascular Division at the Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. He graduated Summa Cum Laude and Phi Beta Kappa (Jr. year) majoring in Mathematics at Dartmouth College in 1985, and received his medical degree at Harvard Medical School in 1989. Dr. Giugliano completed his internship, residency, and chief residency in Los Angeles at Cedars-Sinai Medical Center, an affiliate hospital of UCLA, from 1989-93, and then returned to Boston as a cardiology fellow at the Massachusetts General Hospital (1993-6).
In 1996, Dr. Giugliano joined the Brigham and Women’s Hospital as a Research Fellow in Medicine working with the Thrombolysis in Myocardial Infarction (TIMI) Study Group under the direction of Eugene Braunwald, and completed a Masters of Science in epidemiology at the Harvard School of Public Health. In 1997, he joined the faculty in the Cardiovascular Division of the Brigham and Women’s Hospital and has served as the principal investigator for 9 multicenter clinical trials as part of the TIMI Study Group, where he is now a Senior Investigator.
His areas of research interests include novel antithrombotic and fibrinolytic agents for acute coronary syndromes (ACS), lipid-lowering therapies, and the assessment of outcomes in patients with ACS. He has authored over 100 articles, 25 editorials/book chapters, and given over hundreds of lectures nationally and internationally. Dr. Giugliano is the principal TIMI investigator for the FOURIER (22,500 patient phase III study) and phase II LAPLACE-TIMI 57 trial with a novel lipid lowering agent that inhibits PCSK-9 and the EARLY ACS trial investigator early use of eptifibatide [IntegrelinTM] in high-risk nSTE-ACS. He is also a co-investigator and member of the Operations Committee for the IMPROVE-IT trial comparing VytorinTM to Simvastatin in 18,000 patients post ACS, and for the ENGAGE-AF TIMI 48 Trial of a novel oral factor Xa inhibitor (edoxaban) in 21,000 patients with atrial fibrillation.
Dr. Giugliano was the principal investigator at BWH for a number of additional trials including the AVANTE-GARDE-TIMI 43, PROVE IT-TIMI 22, A2Z, and TIMI 11b studies, and has served on numerous Data Safety Monitoring Boards, clinical endpoint committees, and Holter/ECG Core Laboratories. Dr Giugliano also continues to participate in research projects with the Massachusetts General Hospital Unstable Angina/Myocardial Infarction Research Group directed by Dr. Christopher O’Donnell and the MGH Coronary Clinical Trials Group under the direction of Dr. Ik-Kyung Jang. Dr. Giugliano is an active participant in the clinical activities in the Cardiovascular Medicine Division attending in the Levine Cardiac Intensive Care Unit, telemetry unit, and consult services, and seeing patients in a busy growing outpatient practice.
Dr. Giugliano lives in Westwood, MA with his wife and four children. His other interests include music, baseball, hockey, running, mathematics, and gardening.